It’s a crucial moment for the cell and gene therapy field. At the American Society of Gene & Cell Therapy’s annual meeting, several trends emerged: In vivo CAR-T is everywhere, CRISPR comes for Alzheimer’s and FDA officials took the stage.
BOSTON — Greetings from Boston, where I’ve been on the ground covering the American Society of Gene & Cell Therapy’s annual meeting all week.
It’s a …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The emerging cancer treatment that’s exciting scientists: ‘We’ve just scratched the surface on what’s possible’
Astellas treatment offers new hope to a devastated rare disease community
CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
Integrated CDO capabilities reduce early development complexity
Gene therapy viruses linked to a boy's tumor
BeOne wins FDA approval in lymphoma race
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
Create Medicines raises $122M to bolster in vivo CAR-T therapies
Scientists link boy’s tumor to gene therapy viruses, in rare finding
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
